View Item 

Show simple item record

Germline genetic variants in men with prostate cancer and one or more additional cancers
dc.contributor.authorPilié, Patrick G.
dc.contributor.authorJohnson, Anna M.
dc.contributor.authorHanson, Kristen L.
dc.contributor.authorDayno, Megan E.
dc.contributor.authorKapron, Ashley L.
dc.contributor.authorStoffel, Elena M.
dc.contributor.authorCooney, Kathleen A.
dc.date.accessioned2017-10-23T17:32:05Z
dc.date.available2018-12-03T15:34:05Zen
dc.date.issued2017-10-15
dc.identifier.citationPilié, Patrick G. ; Johnson, Anna M.; Hanson, Kristen L.; Dayno, Megan E.; Kapron, Ashley L.; Stoffel, Elena M.; Cooney, Kathleen A. (2017). "Germline genetic variants in men with prostate cancer and one or more additional cancers." Cancer 123(20): 3925-3932.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/138930
dc.publisherWiley Periodicals, Inc.
dc.subject.othergene panel
dc.subject.othergermline variants
dc.subject.othermultiple primary malignant neoplasms
dc.subject.otherprostate cancer
dc.subject.othergenetic testing
dc.titleGermline genetic variants in men with prostate cancer and one or more additional cancers
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138930/1/cncr30817.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138930/2/cncr30817_am.pdf
dc.identifier.doi10.1002/cncr.30817
dc.identifier.sourceCancer
dc.identifier.citedreferenceRichards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17: 405 ‐ 424.
dc.identifier.citedreferenceGleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S. Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers. Prostate. 2016; 76: 1135 ‐ 1145.
dc.identifier.citedreferenceMateo J, Carreira S, Sandhu S, et al. DNA‐repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015; 373: 1697 ‐ 1708.
dc.identifier.citedreferencePritchard CC, Mateo J, Walsh MF, et al. Inherited DNA‐repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016; 375: 443 ‐ 453.
dc.identifier.citedreferenceRobinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161: 1215 ‐ 1228.
dc.identifier.citedreferenceRaymond VM, Mukherjee B, Wang F, et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol. 2013; 31: 1713 ‐ 1718.
dc.identifier.citedreferenceHaraldsdottir S, Hampel H, Wei L, et al. Prostate cancer incidence in males with Lynch syndrome. Genet Med. 2014; 16: 553 ‐ 557.
dc.identifier.citedreferenceStadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol. 2014; 32: 687 ‐ 698.
dc.identifier.citedreferenceRosso S, De Angelis R, Ciccolallo L, et al; EUROCARE Working Group. Multiple tumours in survival estimates. Eur J Cancer. 2009; 45: 1080 ‐ 1094.
dc.identifier.citedreferenceXu LL, Gu KS. Clinical retrospective analysis of cases with multiple primary malignant neoplasms. Genet Mol Res. 2014; 13: 9271 ‐ 9284.
dc.identifier.citedreferenceMitchell G, Ballinger ML, Wong S, et al; International Sarcoma Kindred Study. High frequency of germline TP53 mutations in a prospective adult‐onset sarcoma cohort. PLoS One. 2013; 8: e69026.
dc.identifier.citedreferenceBallinger ML, Goode DL, Ray‐Coquard I, et al; International Sarcoma Kindred Study. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016; 17: 1261 ‐ 1271.
dc.identifier.citedreferenceWhitworth J, Hoffman J, Chapman C, et al. A clinical and genetic analysis of multiple primary cancer referrals to genetics services. Eur J Hum Genet. 2015; 23: 581 ‐ 587.
dc.identifier.citedreferenceChang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J Med Genet. 2012; 49: 433 ‐ 436.
dc.identifier.citedreferenceHarrison SM, Riggs ER, Maglott DR, et al. Using ClinVar as a resource to support variant interpretation. Curr Protoc Hum Genet. 2016; 89: 8.16.1‐8.16.23.
dc.identifier.citedreferenceRehm HL, Berg JS, Brooks LD, et al; ClinGen. ClinGen–the clinical genome resource. N Engl J Med. 2015; 372: 2235 ‐ 2242.
dc.identifier.citedreferenceHart SN, Ellingson MS, Schahl K, et al. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate‐resistant prostate cancer. BMJ Open. 2016; 6: e010332.
dc.identifier.citedreferenceMaier C, Herkommer K, Luedeke M, Rinckleb A, Schrader M, Vogel W. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations. Prostate. 2014; 74: 1444 ‐ 1451.
dc.identifier.citedreferenceNa R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017; 71: 740 ‐ 747.
dc.identifier.citedreferenceMeric‐Bernstam F, Brusco L, Daniels M, et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. 2016; 27: 795 ‐ 800.
dc.identifier.citedreferenceMork ME, You YN, Ying J, et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol. 2015; 33: 3544 ‐ 3549.
dc.identifier.citedreferenceSchrader KA, Cheng DT, Joseph V, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2016; 2: 104 ‐ 111.
dc.identifier.citedreferenceZhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015; 373: 2336 ‐ 2346.
dc.identifier.citedreferenceMeeks HD, Song H, Michailidou K, et al. BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers. J Natl Cancer Inst. 2016; 108 ( 2 ). pii: djv315.
dc.identifier.citedreferenceJemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015; 314: 2054 ‐ 2061.
dc.identifier.citedreferenceEwing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate‐cancer risk. N Engl J Med. 2012; 366: 141 ‐ 149.
dc.identifier.citedreferenceXu J, Lange EM, Lu L, et al; International Consortium for Prostate Cancer Genetics. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet. 2013; 132: 5 ‐ 14.
dc.identifier.citedreferenceBeebe‐Dimmer JL, Hathcock M, Yee C, et al. The HOXB13 G84E mutation is associated with an increased risk for prostate cancer and other malignancies. Cancer Epidemiol Biomarkers Prev. 2015; 24: 1366 ‐ 1372.
dc.identifier.citedreferenceHoffmann TJ, Sakoda LC, Shen L, et al. Imputation of the rare HOXB13 G84E mutation and cancer risk in a large population‐based cohort. PLoS Genet. 2015; 11: e1004930.
dc.identifier.citedreferenceLaitinen VH, Wahlfors T, Saaristo L, et al. HOXB13 G84E mutation in Finland: population‐based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2013; 22: 452 ‐ 460.
dc.identifier.citedreferenceCastro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause‐specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015; 68: 186 ‐ 193.
dc.identifier.citedreferenceCastro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31: 1748 ‐ 1757.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr30817.pdf
Size:
238.0KB
Format:
PDF
View/Open
Name:
cncr30817_am.pdf
Size:
895.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.